SHIRE PLC: Annual Report and Accounts

April 4, 2008

Annual Report and Accounts for the year ended December 31, 2007

Copies of the above document have been submitted to the UK Listing Authority
and will shortly be available for inspection at the UK Listing Authority's
Document Viewing Facility, which is situated at:

Financial Services Authority
25 the North Colonnade
Canary Wharf
London
E14 5HS

Tel: [phone]

This document may also be viewed on the Company's website www.shire.com

T May
Company Secretary

For further information please contact:

Investor Relations  Cléa Rosenfeld (Rest of the World)       [phone]  
                                                                               
                    Eric Rojas (North America)               [phone]   

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit and hyperactivity disorder (ADHD),
human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The
structure is sufficiently flexible to allow Shire to target new therapeutic
areas to the extent opportunities arise through acquisitions. Shire's
in-licensing, merger and acquisition efforts are focused on products in niche
markets with strong intellectual property protection either in the US or
Europe. Shire believes that a carefully selected portfolio of products with
strategically aligned and relatively small-scale sales forces will deliver
strong results.

For further information on Shire, please visit the Company's website: 
www.shire.com.



Hampshire International Business Park             
Chineham Basingstoke                              
Hampshire RG24 8EP                                
United Kingdom                                    
Tel [phone]                            
Fax [phone]                            
www.shire.com                                     
                                                  
Press Release                                     

Registered in England 2883758 Registered Office as above



END